Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2026-01-06 @ 10:37 PM
Study NCT ID:
NCT02086604
Status:
COMPLETED
Last Update Posted:
2022-02-17
First Post:
2014-03-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor:
Washington University School of Medicine
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma, Large B-Cell, Diffuse | View |
Keywords: